Skip to main content
Premium Trial:

Request an Annual Quote

SNP Applications Seen Saving Healthcare Industry $1 Billion by 2010

NEW YORK, March 12 – The ability to identify and assess SNPs will help to increase treatment efficacy and reduce adverse drug reactions, helping to save the healthcare industry more than $1 billion over the next decade, a survey released Monday by Front Line Strategic Management Consulting said.

The Foster City, Calif.-based consultancy said that treatment efficacy could increase by 32 percent over current levels while adverse drug reactions could be reduced by up to 25 percent.

In addition, Front Line estimated that cost savings from pharmacogenomics could rise to $33 million per drug by the year 2010.

“Driving the savings will be SNP genotyping, which will directly reduce clinical trial sample size and subsequently the overall length of clinical development,” Front Line said. “The SNP genotyping market will experience exponential growth through 2005 due to an increased number of compounds for which SNP genotyping will be utilized in clinical trials. The adoption of this technology will eventually drive growth to an expected peak in 2005 as it reaches over a billion dollars in value.” 

After studying a drug already on the market, Front Line estimated that revenues would have been $3.5 billion, or 45 percent, higher over the life of the drug had pharmacogenomics been applied to the drug’s development. 

“This 45% increase in revenues was obtained by decreasing the overall length of the drug discovery and development process. This would have allowed for earlier market introduction and thereby, extend the time for revenue growth,” Front Line said.

The Scan

Looking for Omicron

NPR reports that SARS-CoV-2 testing in the US has gotten better but also that some experts say more needs to be done to better track the Omicron variant.

Holmes Alleges Abuse

The Associated Press reports that Theranos' Elizabeth Holmes has testified at her wire fraud trial that her business and romantic partner abused her.

Bit More Diverse, But More to Do

While Black and Hispanic patients are more likely to participate in cancer clinical trials than previously, they are still underrepresented, according to US News & World Report.

PNAS Papers on Yeast Gene Silencing, Zika Virus Inhibition, Immunoglobulin Hypermutation

In PNAS this week: gene silencing in Saccharomyces cerevisiae, possible neuroprotective role for SHFL in a mouse model of Zika virus infection, and more.